the company recently released a new antipsychotic drug, arastata, long acting version of abilify, makes for people with schizophrenia to stay on their meds. we've seen growth in vivatrol, once monthly injection, helps prevent recovering alcoholics and opioid addicts from relapsing. president obama signed the comp hencive addiction and recovery act which could expand the market for vivitrol, making it available at 6,500 rehab centers that didn't previously offer this drug. the company has intriguing products in its pipeline, including a depression drug that flamed out in january, but trying to get back on track of presenting data, a couplee iing month. i think it's worth checking in with richard pops, chairman, ceo of alkermes. welcome back to "mad money." richard, we missed -- it was a tough period for the company. i want to talk about this opioid situation because as long as you have been on the show, you have told us that this crisis was coming. the whole time. >> that's right. >> it's happened. what can be done? >> you know, it's gratifying in one sense and horrifying in another sens